Physician profile
Heather Lee
NPI 1578938338
$6,107.47
in general payments reported to CMS, 2019-2025
44 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $505 · 2022: $1,304 · 2023: $1,521 · 2024: $1,772 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,722 · Education: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,722.49 |
| Education | $575.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,030.42 | 2021-2025 | Piqray, Kisqali |
| Gilead Sciences, INC. | $392.88 | 2022-2025 | Trodelvy |
| Astellas Pharma US INC | $374.47 | 2022-2025 | Xtandi, Xospata, Cresemba |
| Abbvie INC. | $342.43 | 2023-2025 | |
| Seagen INC. | $336.53 | 2022-2023 | Tukysa, Adcetris |
| Lilly USA, LLC | $310.59 | 2021-2024 | Verzenio, Jaypirca |
| Celgene Corporation | $272.40 | 2022-2025 | Reblozyl, Opdualag |
| Adaptive Biotechnologies Corporation | $230.64 | 2022-2025 | Clonoseq |
| Pfizer INC. | $224.92 | 2021-2024 | |
| Incyte Corporation | $223.63 | 2021-2024 | Jakafi |
| Janssen Biotech, INC. | $215.85 | 2022-2025 | Erleada, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $208.97 | 2021-2024 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $190.97 | 2021-2025 | Opdivo, Opdualag |
| Amgen INC. | $180.75 | 2021-2023 | Lumakras |
| Astrazeneca Pharmaceuticals LP | $171.82 | 2022-2025 | Lynparza, Imfinzi |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.